Vericel Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Vericel ( NASDAQ:VCEL ) Second Quarter 2025 Results Key Financial Results Revenue: US$63.2m (up 20% from 2Q 2024). Net...
| Ticker |
VCEL
|
| CIK | 0000887359 |
| SIC | 2836 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Biological Products, Except Diagnostic Substances |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Vericel Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues LagVericel ( NASDAQ:VCEL ) Second Quarter 2025 Results Key Financial Results Revenue: US$63.2m (up 20% from 2Q 2024). Net... Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue EstimatesVericel (VCEL) delivered earnings and revenue surprises of +75.00% and -1.33%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock? Vericel Reports Second Quarter 2025 Financial ResultsTotal Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74% Adjusted EBITDA Growth of 112% to $13.4 Million, with Adjusted EBITDA Margin Increase of More than 900 Basis Points to 21% Approximately 600 MACI Arthro Surgeons Trained to Date Received FDA IND Clearance for Phase 3 MACI Ankle Clinical Study Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Vericel Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue EstimatesWave Life Sciences (WVE) delivered earnings and revenue surprises of -6.90% and -31.16%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock? High Growth Tech Stocks In The US MarketThe United States market has shown robust performance, rising 1.7% in the last week and 18% over the past year, with all sectors contributing to this upward trend and earnings projected to grow by 15% annually in the coming years. In such a dynamic environment, identifying high growth tech stocks involves assessing factors like innovation potential, scalability, and their ability to capitalize on technological advancements within these favorable market conditions. |